• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿毒症患者纤维蛋白溶解功能受损:四种不同透析方案的部分和可变纠正作用

Impaired fibrinolysis in uremia: partial and variable correction by four different dialysis regimes.

作者信息

Canavese C, Stratta P, Pacitti A, Mangiarotti G, Racca M, Oneglio R, Vercellone A

出版信息

Clin Nephrol. 1982 Feb;17(2):82-9.

PMID:7067170
Abstract

In addition to a hemorrhagic diathesis, uremia is accompanied by a clotting tendency, caused by a marked fall in fibrinolytic capacity. Measurement of lysis time of whole blood diluted with phosphate and acetate buffers and of euglobulin lysis times showed that accumulation of inhibitors is primarily responsible. These probably belong to the class of small molecules abnormally retained in uremia. Hemodialysis (HD) offers the best method of correction, mainly because of better elimination of these inhibitors. In contrast, hemofiltration (HF) and, particularly, intermittent peritoneal dialysis (IPD) are much less effective. In IPD, protein loss via the peritoneum is also responsible for a loss of fibrinolytic activators, so that fibrinolysis becomes even poorer, exposing the patient to an increased risk of vascular complications.

摘要

除了出血素质外,尿毒症还伴有凝血倾向,这是由纤溶能力显著下降引起的。用磷酸盐和醋酸盐缓冲液稀释的全血溶解时间以及优球蛋白溶解时间的测量表明,抑制剂的积累是主要原因。这些抑制剂可能属于尿毒症时异常潴留的小分子类别。血液透析(HD)是最佳的纠正方法,主要是因为能更好地清除这些抑制剂。相比之下,血液滤过(HF),尤其是间歇性腹膜透析(IPD)的效果要差得多。在IPD中,通过腹膜的蛋白质丢失也导致纤溶激活剂的丢失,从而使纤溶作用更差,使患者面临血管并发症风险增加的问题。

相似文献

1
Impaired fibrinolysis in uremia: partial and variable correction by four different dialysis regimes.尿毒症患者纤维蛋白溶解功能受损:四种不同透析方案的部分和可变纠正作用
Clin Nephrol. 1982 Feb;17(2):82-9.
2
[Effect of chromatographic fractions of blood ultrafiltrates of patients with chronic uremia on the fibrinolytic activity]].
Pol Tyg Lek. 1990;45(40-41):810-3.
3
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
4
Dialysis and the elderly: an underestimated problem.透析与老年人:一个被低估的问题。
Kidney Blood Press Res. 2008;31(5):330-6. doi: 10.1159/000164277. Epub 2008 Oct 21.
5
An analysis of the effectiveness and benefits of peritoneal dialysis and haemodialysis using Nigerian made PD fluids.使用尼日利亚产腹膜透析液对腹膜透析和血液透析的有效性及益处进行的分析。
Afr J Med Med Sci. 2005 Sep;34(3):227-33.
6
[Acid-base equilibrium in uremia: effect of continuous ambulatory peritoneal dialysis and hemodialysis].
G Clin Med. 1981 Sep;62(9):624-33.
7
[Some parameters of platelet activation in patients with uremia before and after hemodialysis (HD)].[尿毒症患者血液透析前后血小板活化的一些参数]
Przegl Lek. 2002;59(12):980-3.
8
Global fibrinolytic capacity in children on dialysis.接受透析治疗儿童的全球纤溶能力。
Thromb Res. 2005;115(3):185-9. doi: 10.1016/j.thromres.2004.08.014.
9
[The presence of trace quantities of aluminum in dialysates as a risk factor in peritoneal dialysis].[透析液中微量铝的存在作为腹膜透析的一个危险因素]
Boll Soc Ital Biol Sper. 1981 Mar 30;57(6):659-65.
10
Profound mishandling of protein glycation degradation products in uremia and dialysis.尿毒症和透析中蛋白质糖基化降解产物的严重处理不当。
J Am Soc Nephrol. 2005 May;16(5):1471-85. doi: 10.1681/ASN.2004080635. Epub 2005 Mar 30.

引用本文的文献

1
Fibrinolytic activity in renal venous blood in man.人体肾静脉血中的纤溶活性。
Klin Wochenschr. 1986 Jul 1;64(13):587-9. doi: 10.1007/BF01735260.
2
The role of intravascular coagulation in pregnancy related acute renal failure.
Arch Gynecol Obstet. 1988;243(4):207-14. doi: 10.1007/BF00932269.